Clinical Trials Directory

Trials / Unknown

UnknownNCT03301389

Cardiac Magnetic Resonance for Early Detection of Chemotherapy or Radiation Therapy Induced Cardiotoxicity in Breast Cancer (CareBest)

Status
Unknown
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
Yonsei University · Academic / Other
Sex
Female
Age
17 Years – 80 Years
Healthy volunteers
Accepted

Summary

Chemotherapy or radiation therapy-induced cardiotoxicity are well-recognized side effects in patients with cancer. The clinical significance of cardiotoxicity is growing with increasing cancer survivor-ship. Left ventricular (LV) functional assessment is the standard of reference to diagnose chemotherapy- or radiation therapy-induced cardiotoxicity. The investigators will investigate the usefulness of T1 mapping parameters for early detection and prediction of chemotherapy-, radiation therapy-, or other therapy-induced cardiotoxicity in breast cancer patients This study aimed to achieve early detection of chemotherapy- or radiation therapy-induced cardiotoxicity using T1 mapping magnetic resonance imaging (MRI) and determine a prognostic imaging factor of chemotherapy- or radiation therapy-induced cardiotoxicity in patients treated for breast cancer.

Detailed description

Screening and follow-up cardiac magnetic resonance imaging (CMR) protocols for diagnosis of cardiotoxicity will be conducted in patients with breast cancer who have received or are planned to receive treatment for breast cancer. The protocol will include T1 and T2 mapping and cine imaging of the LV myocardium.

Conditions

Interventions

TypeNameDescription
OTHERCardiac magnetic resonance imagingThe cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.

Timeline

Start date
2016-12-01
Primary completion
2025-01-01
Completion
2025-01-01
First posted
2017-10-04
Last updated
2019-01-11

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03301389. Inclusion in this directory is not an endorsement.